1. Ruthenium-based chemotherapeutics: are they ready for prime time?

   • Emmanuel S. Antonarakis
   • Ashkan Emadi

   Mini Review 06 March 2010 Pages: 1 - 9

   

2. N₃-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU

   • Xiaofan Zhang
   • Julia Li Zhong
   • Xianjun Qu

   Original Article Open access 16 September 2009 Pages: 11 - 19

   

3. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro

   • Hui-Jun Zhou
   • Jia-Li Zhang
   • Xiao-E Lou

   Original Article 16 September 2009 Pages: 21 - 29

   

4. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer

   • Jin Young Kim
   • Young Rok Do
   • Hong Suk Song

   Original Article 18 September 2009 Pages: 31 - 36

   

5. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer

   • Yunfei Cao
   • Lidan Liu
   • Feng Gao

   Original Article 17 September 2009 Pages: 37 - 42

   

6. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models

   • Alberto Gabizon
   • Dina Tzemach
   • Samuel Zalipsky

   Original Article 25 September 2009 Pages: 43 - 52

   

7. A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva^®, OSI-774) in patients with advanced solid tumors of epithelial origin

   • M. Ranson
   • H. Shaw
   • I. Judson

   Original Article 03 December 2009 Pages: 53 - 58

   

8. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer

   • Kaisa Leea Sunela
   • Sanna Koskinen
   • Pirkko-Liisa Kellokumpu-Lehtinen

   Original Article 22 September 2009 Pages: 59 - 67

   

9. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells

   • Jose Prados
   • Consolación Melguizo
   • Antonia Aránega

   Original Article 22 September 2009 Pages: 69 - 78

   

10. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma

    • Andréia Hanada Otake
    • Ana Lucia Mattar
    • Roger Chammas

    Original Article 22 September 2009 Pages: 79 - 87

    

11. Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer

    • Norikazu Masuda
    • Takahiro Nakayama
    • Junichi Sakamoto

    Original Article 19 September 2009 Pages: 89 - 94

12. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients

    • Kimie Sai
    • Yoshiro Saito
    • Hironobu Minami

    Original Article 22 September 2009 Pages: 95 - 105

    

13. Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer

    • Masafumi Yamaguchi
    • Sadanori Takeo
    • Hironori Matsuzawa

    Original Article 07 October 2009 Pages: 107 - 112

14. Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge

    • Elodie Vauléon
    • Habiba Mesbah
    • Pierre Kerbrat

    Original Article 27 September 2009 Pages: 113 - 120

    

15. Effects of extracellular purines on cytotoxicity of methotrexate

    • Li Chong
    • Guoyi Ma
    • Martin H. N. Tattersall

    Original Article 27 September 2009 Pages: 121 - 127

    

16. High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors

    • Metin Kurtoglu
    • Katherine Philips
    • Theodore J. Lampidis

    Original Article 25 September 2009 Pages: 129 - 140

    

17. Peroxisome proliferator-activated receptor γ-dependent activity of indole ring-substituted 1,1-bis(3′-indolyl)-1-(p-biphenyl)methanes in cancer cells

    • Jingjing Guo
    • Sudhakar Chintharlapalli
    • Stephen Safe

    Original Article 13 October 2009 Pages: 141 - 150

    

18. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors

    • Bhuvaneswari Ramaswamy
    • Tanios Bekaii-Saab
    • Charles L. Shapiro

    Original Article 23 September 2009 Pages: 151 - 158

    

19. The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study

    • Shabnam N. Sani
    • Katherine Henry
    • Timothy J. Maher

    Original Article 09 October 2009 Pages: 159 - 169

    

20. Sensitivity of breast cancer cell lines to recombinant thiaminase I

    • Shuqian Liu
    • Noel R. Monks
    • Jeffrey A. Moscow

    Original Article 15 October 2009 Pages: 171 - 179

    

21. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

    • Dana Rathkopf
    • Bryan Y. Wong
    • Howard I. Scher

    Clinical Trial Report 09 March 2010 Pages: 181 - 189

    

22. A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie

    • Volker Kaechele
    • Markus Moehler
    • Thomas Seufferlein

    Clinical Trial Report 31 March 2010 Pages: 191 - 195

23. “Metronomic” chemotherapy in advanced soft tissue sarcomas

    • Antoine Italiano
    • Maud Toulmonde
    • Binh Bui

    Short Communication 25 February 2010 Pages: 197 - 202

    

24. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

    • Martin Pölcher
    • Meike Eckhardt
    • Christian Rudlowski

    Short Communication 05 March 2010 Pages: 203 - 207